Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal amphotericin b + miltefosine
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Liposomal amphotericin B + miltefosine is a combination therapy used primarily for the treatment of visceral leishmaniasis, including in patients co-infected with HIV. Liposomal amphotericin B is a lipid-based formulation of the polyene antifungal and antiprotozoal agent amphotericin B, designed to improve drug delivery to macrophages in affected organs and reduce toxicity compared to conventional formulations. Miltefosine is an oral alkylphosphocholine compound with antileishmanial activity. The combination leverages the rapid parasite clearance of liposomal amphotericin B and the sustained activity of miltefosine, showing synergistic effects in vitro and improved clinical outcomes in some studies. This regimen has been evaluated in phase III trials for visceral leishmaniasis/HIV coinfection[1][2][3][7].
- Brand names
- AmBisome + miltefosine
- Other names
- amphotericin B liposomeamphotericin B lipid complex (for related formulations)alkylphosphocholine (for miltefosine, as a class)
02
Targets
Ergosterol
Beyond the preview
Go deeper on liposomal amphotericin b + miltefosine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal amphotericin b + miltefosine.